E
Epitel
Platform for brain health insight backed by powerful data analytics
About Epitel
Epitel Inc., based in Salt Lake City, specializes in developing advanced wearable technology for epilepsy monitoring and control. Their flagship product, Epilog, is a non-invasive, 24/7 seizure detection system that uses EEG (electroencephalogram) to record and monitor seizure activity. Designed for continuous use, Epilog can be worn at home, during sleep, or on the go, providing users and their healthcare providers with accurate, real-time data to better understand and manage epilepsy. The device is wireless, utilizing Bluetooth technology, and is easy to use with a simple adhesive application and rechargeable battery. Although still in development and not yet FDA-approved, Epilog aims to offer a medical-grade solution that empowers individuals with epilepsy by delivering personalized, long-term brain health insights. Epitel's business model focuses on creating a subscription-based service for continuous monitoring and data analytics, targeting individuals with epilepsy, their families, and healthcare providers. The company operates in the medical device and health technology market, aiming to generate revenue through device sales and ongoing subscription fees for data services.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Salt Lake City, United States
- Employees
- 57
- Open positions
- 7
- Dealroom signal
- 51.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Neurology, Mental Health, Spinout, Wearable, remote health monitoring, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech, Connected Device
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2026 | $26M | $104M | Genoa Ventures · Catalyst Health Ventures | ↗ |
| SERIES A✓Equity / VC | Feb 2022 | $13M | $50M | Genoa Ventures · OSF Ventures · Dexcom · Catalyst Health Ventures | ↗ |
Growth signals
Latest recorded traffic for Epitel is 6K monthly website visits, up 122.2% over the last three months. Epitel's team grew 7.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
Ideaship Fund
Series A6 investors entered at this stage
Genoa Ventures- CVCatalyst Health Ventures
OSF Ventures
Dexcom- WHWavemaker Three-Sixty Health
MedMountain Ventures
Other known investors4 additional known investors
University of Utah- DVDexcom Ventures
OSF
Southwest-Midwest National Pediatric Device Innovation Consortium
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Epitel on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Epitel’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.